Centene's Rebound Runs on 8.9 Million Drug-Plan Members, Not the Marketplace

Centene posted $0.58 of Q3 2026 adjusted EPS against a $0.10 consensus and raised its 2026 adjusted EPS floor above $5.20. Medicare revenue grew 20% while Commercial fell 21%. The stock is up 88% in a year, yet management says the real 2027 starting point is about $4.70.

CNC · Health Care · November 06, 2026

S&P 500 Position

Centene is one of the managed care constituents in the S&P 500 Health Care sector, alongside UnitedHealth, Elevance, Cigna, CVS, Humana and Molina. Its closest competitor is Molina, the other large Medicaid- and Marketplace-focused plan, and the two stocks often trade together on Medicaid rate and ACA risk-pool news. The post-election setup splits the group. Hospital stocks rallied after Democrats took Congress, and Warren's breakup rhetoric targets UnitedHealth's vertical integration. That puts pressure on vertically integrated giants more directly than on a pure-play government insurer like Centene.

Index Weight: Data unavailable | Rank: Data unavailable

Company Overview

Centene is no longer an Obamacare growth story. It is a margin-repair story built on Medicare. Medicare segment revenue rose 20% year over year to $11.26B in Q3 2026, and Medicare PDP membership climbed to 8.9 million from 8.0 million. Over the same period, Commercial revenue fell 21% to $8.7B. Total managed care membership dropped 2.3 million, or 8%, to 25.7 million. Q3's consolidated health benefits ratio (HBR) came in at 92.7%, better than expected. Medicare drove the beat, while Medicaid and Marketplace ran on plan. The quarter rescued the year: Centene lifted its 2026 adjusted diluted EPS floor to greater than $5.20 and its GAAP floor to greater than $3.46. The business problem Centene is solving is fundamentally a data problem. In the Marketplace, profitability depends on risk-adjustment transfers. Centene's argument that its members carry higher acuity than the market was validated by the June Wakely report, which strengthened its position in the zero-sum ACA risk pool. In Medicaid, the issue is membership attrition and the acuity mix of whoever remains. Centene now expects Medicaid membership to fall 9% by year-end 2026, worse than its earlier 6-8% forecast. Its membership disclosures now separate 1.35 million 'High Acuity Medicaid' lives from 10.5 million Traditional Medicaid lives. That split is a direct signal that cost modeling by member cohort is now how the company manages the book. The technical story for 2027 is about leadership. Centene hired Fannie Mae CIO Bradley Bolivar as CIO in August 2026. CEO Sarah London described the move as entering 'a new era where data, technology and AI are not just business enablers.' A finance transition follows on January 1, 2027, when Chris Neczypor takes over from CFO Drew Asher. With a 0.8% TTM net margin on $194.7B of revenue, every basis point of medical-cost or administrative-cost improvement is material. That is the context for Centene's technology bet.

Products & Revenue

Centene earns money by underwriting government-sponsored health risk at enormous scale on thin margins. Medicaid remains the core, at $24.0B of Q3 2026 revenue and up 4% year over year, supported by state rate setting and acuity-adjusted capitation. Medicare is now the growth engine and the source of earnings upside. Its $11.3B in Q3 revenue grew 20%, driven by 8.9 million standalone PDP members and 954,400 Medicare Advantage, Supplement and integrated-plan members. Commercial, which is mostly ACA Marketplace, shrank 21% to $8.7B as enrollment contracted. Profitability there depends on risk-adjustment accuracy, not volume. Measured by members, PDP accounts for 34.8% of Centene's 25.7 million lives. Measured by revenue, Medicaid still contributes more than half.

Medicaid (53.3%): Capitated state Medicaid contracts covering 11.9 million members: 10.5 million Traditional and 1.35 million High Acuity. Q3 2026 revenue was $24,039M (+4% YoY), even as membership is projected to fall 9% by year-end.

Medicare (25.0%): Standalone Part D prescription drug plans (8.9 million members) plus Medicare Advantage, Supplement and integrated plans (954,400 members). Q3 2026 revenue was $11,263M (+20% YoY), and this segment drove the better-than-expected HBR.

Commercial (Marketplace + Individual/Group) (19.3%): ACA Marketplace (3.4 million members) plus 497,400 individual and commercial group members. Q3 2026 revenue was $8,700M (-21% YoY), with economics driven by risk-adjustment positioning against the market.

Other / Eliminations (~2.4%): Remainder of the roughly $45.1B in Q3 2026 premium and service revenue not attributed to the three reported segments.

Revenue shares are based on the Q3 2026 press release (Oct 27, 2026) and calculated against roughly $45.1B of Q3 premium and service revenue. Membership comes from the Q3 2026 Form 10-Q (period ended Sept 30, 2026).

Leadership

Sarah M. London

CEO since 2022. London has been CEO since March 2022 and has led Centene through Medicaid redeterminations and the 2026 Marketplace contraction. Her August 2026 hire of a Fannie Mae technology chief signals a clear strategic direction. She described data, technology and AI as more than 'business enablers,' which tells investors she sees them as central to how the company competes, not as back-office tools.

Bradley Bolivar, Chief Information Officer (appointed August 2026): Bolivar was previously CIO at Fannie Mae, where he ran technology for a heavily regulated, government-adjacent financial institution at national scale. That background maps directly onto Centene's mix of Medicaid, Medicare and ACA business. He now owns the data and AI agenda London has put at the center of strategy.

Daniel Finke, Group President, Markets and Commercial (hired April 2026): Finke runs the state-market and Commercial businesses, including a Marketplace book that lost 21% of its revenue year over year. His mandate is repricing and risk-adjustment discipline, not chasing membership.

Michael Carson, Group President, Medicare and Specialty (appointed April 2026): Carson leads the segment that drove the Q3 beat, including 8.9 million PDP members and 20% revenue growth. Centene's 2027 earnings path depends heavily on his book.

Chris Neczypor, Incoming CFO (effective January 1, 2027): Neczypor inherits a guidance framework built on a roughly $4.70 adjusted EPS jump-off point for 2027. He will be the one explaining how Centene gets from there to sustained margin expansion.

Drew Asher, CFO (stepping down December 31, 2026): Asher oversaw the guidance reset and the Q3 recovery. His exit closes the finance chapter that covered Centene's Marketplace repricing.

The AI Angle

AI as an actuarial weapon, led by a mortgage-tech CIO

Centene has not disclosed specific shipped AI products in the available research. Data on named models, vendor partnerships or deployed tools is unavailable. What the record does show is a strategic commitment at the top. In August 2026, London hired Bradley Bolivar from Fannie Mae as CIO and framed the move around 'a new era where data, technology and AI are not just business enablers.' Hiring an external CIO from a regulated financial institution, rather than promoting from within, shows that Centene treats this as a re-platforming effort, not an incremental IT upgrade. The real AI opportunity at Centene is classification and prediction applied to risk pools, not chatbots. The company's 2026 results hinged on how accurately it understood member acuity. The Wakely report confirmed its Marketplace members are sicker than the market average, which matters directly for risk-adjustment transfers. Its 10-Q now separates High Acuity Medicaid (1.35 million lives) from Traditional Medicaid (10.5 million). Its Medicare PDP book of 8.9 million members is a large pharmacy-claims dataset in a market where consumer headlines warn of drug cost increases of up to 50% next year. Better coding accuracy, earlier identification of high-cost members and stronger pharmacy cost forecasting translate directly into HBR improvement, and Centene's TTM net margin is only 0.8%. On talent, Bolivar is the key figure. Fannie Mae's technology challenges involve massive structured datasets, strict regulatory oversight and credit-risk modeling, which closely resemble a Medicaid insurer's work. Details on Centene's internal data science or AI research teams are unavailable in the research. The risk is political as much as technical. Democrats have just won Congress, and Elizabeth Warren is publicly calling to 'break up Big Medicine,' starting with UnitedHealth. Any Centene AI system that affects utilization management, claims or coverage decisions for government-program members will face more scrutiny than a peer's commercial-book tools would. Centene's advantage is the scale of its Medicaid and PDP data. Its weakness is that it operates almost entirely on government revenue, which leaves little room for error with regulators.

Financial Snapshot

Revenue (TTM): $194.7B (TTM through Sept 30, 2026) | Net Income: $1.46B (TTM net income)

Margins: Gross: data unavailable; operating: data unavailable; net 0.8%. Q3 2026 consolidated HBR was 92.7%.

Centene's balance sheet has scale but its earnings are fragile. Net income was $1.46B on $194.7B of revenue, so a one-point HBR change can wipe out or double profits. The Q3 beat of $0.58 against $0.10 consensus and the raised floors confirm the repricing is working. However, management itself puts the 2027 base at about $4.70, below the 2026 guidance floor, which tells investors the 2026 figure includes non-recurring help.

1-Year Performance

$69.74, up 88.0% year over year, which implies a year-ago level near $37.

The rally reflects a recovery from depressed 2025 levels. The main drivers were a large Q3 2026 earnings beat ($0.58 adjusted EPS against $0.10 expected), two upward revisions to the EPS floors, and Medicare outperformance that offset the Marketplace enrollment decline. Simply Wall St still describes the stock as cheap after a 100% run. The next test is whether investors accept the roughly $4.70 2027 jump-off point or treat it as a reset.

Recent News

• “We Need to Break Up Big Medicine”: Warren Targets UnitedHealth as Democrats Win Congress — Yahoo Finance: A Democratic Congress focused on vertical integration in healthcare changes the regulatory environment for every managed care company. It also raises the stakes for any algorithmic claims or coverage decisions made on government-program members.
• Medicare prescription drug costs could jump 50% next year. How to prepare. — Yahoo Finance: Centene has 8.9 million Medicare PDP members, the largest share of its total membership. Part D pricing and cost changes have a direct effect on the segment that drove its Q3 beat.
• Centene (CNC) Stock Still Looks Cheap As Its 100% Run Continues — Simply Wall St: This piece makes the valuation case. At about 13x the 2026 adjusted EPS floor, the market still prices Centene as a low-margin government contractor rather than a recovered compounder.
• Centene Stock Outlook: Is Wall Street Bullish or Bearish? — Yahoo Finance: This summarizes how analyst sentiment has shifted after the Q3 beat and guidance raise.
• Did The Market Read Molina Healthcare Stock Right? — Yahoo Finance: Molina is Centene's closest Medicaid and Marketplace competitor, so read-throughs on rates and acuity between the two companies move both stocks.
• Hospital Stocks Soared as Democrats Took Congress — Yahoo Finance: Hospital stocks rallying on expectations of coverage expansion is a mixed signal for insurers. More covered lives can mean more Medicaid and ACA enrollment, but stronger provider pricing leverage pushes up medical costs.

Fun Fact: More than a third of Centene's 25.7 million members (34.8%, or 8.9 million) are standalone Medicare Part D enrollees. For those members, Centene underwrites only prescription drug risk, with no hospital or physician coverage. Its PDP membership alone is about 2.3 times its entire Commercial book of 3.9 million. Yet the whole Medicare segment, including Medicare Advantage, produced only about 25% of Q3 revenue.